Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-02-08

Clinical Trial Update: Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

A completed Phase 2 study evaluating forodesine hydrochloride in patients with advanced, fludarabine-refractory chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Forodesine hydrochloride (forodesine hydrochloride)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Leukemia, Lymphocytic, Chronic | Phase 2 | Status: COMPLETED